Loading company…
Peptomyc is developing OMO-103, a first-in-class MYC inhibitor for cancer, based in Barcelona, Spain.
Founded in 2014 by Laura Soucek and based in Barcelona, Spain, Peptomyc SL develops cancer therapies, led by OMO-103, a mini-protein MYC inhibitor. OMO-103 is in clinical trials, including a Phase 2 trial for advanced osteosarcoma and a Phase Ib trial for pancreatic ductal adenocarcinoma. In September 2026 the company raised EUR 5.7 million in venture funding from Institut Catala de Finances, and it reported revenue of EUR 0 and EBITDA of EUR -190,151.9 in 2023.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in